Stakeholders Look To Congress To Address Compounding After Court Sidesteps Issue
Stakeholders are looking to Congress to provide clarification of FDA's authority over animal drug compounding following Thursday's dismissal of a closely watched animal drug compounding case that left key issues unresolved and as lawmakers focus on the agency's oversight of drug compounding in the wake of a deadly meningitis outbreak.
You've followed a link to an article or document on InsideHealthPolicy.com.
There are three ways you can access this content.
If you are an InsideHealthPolicy.com subscriber, or you have an active trial subscription, please login here:
Take A Trial Subscription
If you haven't already had a trial subscription to InsideHealthPolicy.com, you can sign up for one right now. Just click on the link below to get started -- you'll get full access for one month, including access to our newsletters, Inside CMS and FDA Week, plus daily news updates by e-mail and much, much more.
Sign up for a trial subscription.
Buy This Article
You can also buy this and other individual InsideHealthPolicy.com articles by going to the InsideHealthPolicy.com NewsStand. Articles are $5 apiece. We'll even give you your first download free.
Here's a direct link to this article on the NewsStand.